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Is the Intestine a Portal of Entry for the Serious COVID-19
Complications of Endotoxemia and Thrombosis?
David H. Alpers, MD
Abstract: Severe acute respiratory syndrome coronavirus 2 infection has been associated with both endotoxemia and
thrombosis of small and large vessels, but the relationship between these 2phenomena has not beenpursued.Oliva et al.
in this issue of Clinical and Translational Gastroenterology demonstrate an association between the 2 findings and
suggest that increased intestinal permeability is a possible mechanism to explain the endotoxemia. Although the
evidence to support this hypothesis is only suggestive, the role of the small intestine in the illness produced by the virus
needs to be further explored.
Clinical and Translational Gastroenterology 2021;12:e00367. https://doi.org/10.14309/ctg.0000000000000367
An amazing amount of data on coronavirus 2019 (COVID-19)
infection has been published over the past year, and of necessity,
much of it is fragmented. The infection is known to induce
endotoxemia measured activity in critically ill patients, nearly all
of which had evidence of 16S RNA amplification in serum, with
proteobacteria the most frequent phylum (1). Moreover, lipo-
polysaccharide (LPS) is elevated in patients with obesity and
diabetes, known risk factors for COVID-19 infection, and LPS
levels are high also in infected patients with cardiac toxicity,
and in other viral illnesses, such as human immunodeficiency
virus (2). COVID-19 infection is also associated with throm-
botic complications through activation of platelets, endothelial
injury from the virus, and abnormal blood flow dynamics (3).
The major mechanism leading to lung thrombosis is dysre-
gulation of angiotensin signaling, leading to inflammation,
with subsequent increased signaling through thrombin and
purinergic receptors to cause platelet activation (4). This latter
mechanism may lead to thrombosis in other organs and be
complicated by coagulopathy from comorbid conditions.
About one-third of severely infected patients have macro-
vascular complications, including venous thromboembolism,
stroke, and acute myocardial infarction (5). Both LPS and se-
vere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
can cause endothelial damage and alter platelet function, and D-
dimer levels can be very high, so the relative importance of endo-
toxemia in the pathogenesis of the thrombosis is not entirely clear.
Despite the occurrence of both endotoxemia and thrombosis in
COVID-19–infectedpatients, studieshavenotpreviously focusedon
the association between these phenomena in the same patients.
The current study by Oliva et al. (6) measured LPS levels and
activity and recorded macrothromboses in a series of patients
with SARS-CoV-2–related pneumonia who were hospitalized
and in some cases required mechanical ventilation. Among 81
patients, 11 (14%) had clinical thrombosis, 5 arterial and 6 ve-
nous, although no other clinical details are provided. LPS levels
were higher in the entire group compared with control outpatient
subjects matched for demographics and clinical conditions. LPS
activity (TLR4 activation) was also increased, as were D-dimer
and high-sensitivity C-reactive protein levels. LPS and D-dimer
independently predicted thrombotic events for each increasing
quartile, but LPS and D-dimer values were not associated. To
evaluate the possible role of the intestine as the entry point for
endotoxin into the body, the authors also measured serum zon-
ulin as a biomarker for intestinal permeability. Zonulin levels
were higher in the patients with COVID-19, and these levels were
correlated with LPS levels. The authors suggest that enhanced gut
permeability may be an underlying mechanism to explain the
observation of endotoxemia as a risk factor for thrombotic events.
The demonstration of the association of LPS and thrombotic
events is a potentially important observation, albeit in a small
sample, as it fits with the previous observations that both endo-
toxemia and thrombosis are part of the spectrum of COVID-19
disease in critically ill patients. Whether this association is caus-
ative or confounded by comorbid conditions is not clear from this
report. Regarding the presence of endotoxemia, whether or not
causative, the suggestion that endotoxin might be entering by
increased gut permeability is not strongly supported by the evi-
dence. Neither LPS nor zonulin are validated biomarkers for
intestinal permeability. LPS enters the body by various mecha-
nisms, of which increased permeability is a minor one, based on
existing data (7). LPS has amuch larger radius (10–15 Å) than the
mean paracellular intestinal pathway (3.6 Å), and the small bowel
is more permeable than the colon and accounts for most of the
effect of tests used to measure gut permeability. Most of the
microbiome, however, resides in the colon in humans. Perhaps
because of this physiology, or because LPS can itself alter gut
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permeability, there is poor correlation between serum LPS and
the gold-standard measurements of gut permeability, most
commonly lactulose-mannitol or lactulose-rhamnose absorption
(8). Similarly, there is a poor correlation of serum zonulin with
gold-standard measurements of gut permeability (9). There are
also 2 other possible explanations for increased LPS inCOVID-19
infection, other than that of altered gut permeability. First, LPS
might be induced in susceptible individuals already harboring low
levels of endotoxemia (2). Second, organisms superimposed on
SARS-CoV-2 infection, in the lung or elsewhere in the body,
could produce LPS (1). The hypothesis that the gut might be an
important portal of entry for gut organisms has been suggested
because of the high concentration in the small bowel of theACE-2
receptor, required for entry of SARS-CoV-2 into cells (10). In fact,
SARS-CoV-2 has been shown to infect human gut organoids, but
the intracellular virus is positioned to be apically secreted, so entry
into the body through enterocytes has not yet been demonstrated
(11). Moreover, the virus is rapidly inactivated by gastric fluid,
and functional virus has not usually been detected in feces (11).
Thus, it is still uncertainwhether the intestine functions as a site of
active SARS-CoV-2 replication and entry into the body.
Despite these questions about the role of the small intestine,
there is some evidence in other systems that SARS-CoV-2 in-
fection might be capable of altering gut permeability. In a study
using multiple human intestinal cancer cell lines, SARS-CoV-2
increased the epithelial-to-mesenchymal transition, breaking down
the alveolar epithelial barrier, and resulting in downregulation of
genes associated with tight junctions (12). No physiological or
morphological demonstration of altered permeability was demon-
strated, and because altered epithelial-to-mesenchymal transition is
a heightened pathway in cancer cells, there is need to demonstrate
this phenomenon in nonmalignant intestinal cells. Alternatively, it is
possible that the effects of SARS-CoV-2 infection in the lung or the
virus itself might spread from the lung to the intestine, thus altering
barrier function (13). However, the possibilities are speculative at
present, and the zonulin data in this article suggest only the possi-
bility of altered gut barrier function. Further work will be needed to
determine whether the intestine plays an important role in the
pathogenesis of COVID-19, either by providing a portal of entry for
the virus itself, or by allowing bacterial or LPS translocation into the
body of severely infected patients.
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